A director at Evonik Industries AG bought 11,487 shares at 17.395EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully reflec...
Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété dans ...
>Net savings bridge into 2025 clearly positive expected, underpinning current consensus growth, operational tailwind on top - We hosted a roadshow with Senior IR of Evonik, confirming good self-help-based visibility into 2025. Factor cost inflation of +€ 200m in 2025 is expected to be largely compensated by internal process/yield optimisation, leaving mid 2-digit €m net factor increase as an initial tailwind. € 175m higher cost savings from TailorMade and continuing o...
Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...
Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...
>Q3 EBITDA 1% ahead of consensus at € 577m, up 19% y/y - The group’s expected solid Q3 results came out today, with € 577m of adj. EBITDA, 1% ahead of the css, gaining 19% y-o-y (cons/ODDO € 573m/€ 564m), flat q-o-q compared to strong Q2 24 results of € 578m and in line with 'largely flat q-o-q' company guidance.Spec. additives and smart materials remain firm, maintained solid methionine prices vs. q-o-q volume recovery - net positive - Summer lull se...
The long financial duration that Cellnex enjoys implies high sensitivity of the valuation to discount rates. After a long challenging two-year period, we now see a more favourable economic environment ahead. Factors such as the potential for interest rate cuts and inflation nearing Cellnex’s sweet spot, coupled with a strong organic performance and newly implemented strategic measures—particularly deleveraging and further efficiencies on both Opex and Capex—create a positive backdrop....
The long financial duration that Cellnex enjoys implies high sensitivity of the valuation to discount rates. After a long challenging two-year period, we now see a more favourable economic environment ahead. Factors such as the potential for interest rate cuts and inflation nearing Cellnex’s sweet spot, coupled with a strong organic performance and newly implemented strategic measures—particularly deleveraging and further efficiencies on both Opex and Capex—create a positive backdrop....
>Good Q3 results ahead, despite headwinds in Performance Materials (upstream) - Evonik is due to report good Q3 2024 results on 6 November 2024. We project adj. EBITDA of € 564m, up 16% y/y and slightly down by 3% q/q compared to € 578m reported in Q2 24. Summer lull may sequentially weigh on Specialty Additives (€ 200m vs. € 220m in Q2 24). We expect sequential volume recovery from the restart of its expanded methionine capacity in Singapore (from 300kt to 340ktpy) t...
Sartorius is set to outperform the underlying biopharmaceutical market based on higher exposure to novel biologics and its focus on single-use components. Destocking is likely to end soon but the changing ordering pattern could distort order intake as KPI and organic growth should recover faster. In our view, the expected cut to its FY 2024 guidance is already largely reflected in the share price. Based on the expected turnaround, we have upgraded to Outperform with a new target price...
Sartorius is set to outperform the underlying biopharmaceutical market based on higher exposure to novel biologics and its focus on single-use components. Destocking is likely to end soon but the changing ordering pattern could distort order intake as KPI and organic growth should recover faster. In our view, the expected cut to its FY 2024 guidance is already largely reflected in the share price. Based on the expected turnaround, we have upgraded to Outperform with a new target price...
>Q2 potentially better than initially thought, EBITDA up 6% q-o-q excluding licence income reported in Q1 - Evonik is due to report a good set of Q2 results on 1 August. We project adj. EBITDA to gain 19% y-o-y to € 536m (css € 531m) and 3% q-o-q compared with Q1 2024 results of € 522m and flat q-o-q company guidance. Q1 included € 15m licence income from selling a HPPO processing technology licence. Adjusted for that, Q2 2024 EBITDA may grow 6% q-o-q. Ex...
Moody's Ratings (Moody's) affirmed Evonik Industries AG (Evonik or the company) long-term issuer rating at Baa2. Concurrently Moody's has affirmed the Baa2 ratings of all of Evonik's outstanding senior unsecured notes, the (P)Baa2 rating of Evonik's senior unsecured MTN programme and the Ba1 rating ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.